Today: 16 June 2026
Innodata Pops After Analyst Sets $140 Price Target Amid AI Data Surge
16 June 2026
1 min read

Innodata Pops After Analyst Sets $140 Price Target Amid AI Data Surge

New York, June 16, 2026, 13:50 ET

  • Innodata was up around 11.3% intraday, trading close to $110.97.
  • BWS Financial raised its price target to $140 and kept its “top pick” rating.
  • Q2 results are the next catalyst, with focus on whether management sticks to its higher 2026 growth view.

Innodata Inc. shares jumped Tuesday, with traders rotating into one of the more volatile AI data stocks. The Nasdaq-listed name was last at $110.97, up $11.31, or 11.3%. The day’s range ran from $98.12 to $113.73, putting market cap around $3.96 billion. Google Finance showed a 52-week range from $34.23 up to $125.14, bringing Innodata closer to its recent peak. Its beta stood at 2.83, a sign of how much INOD can swing. Google

Renewed analyst calls gave Innodata a push Monday. BWS Financial lifted its price target to $140 from $110, keeping Innodata as a “top pick,” MarketBeat said, citing Benzinga. Wedbush also bumped its target up to $120 from $100 and stayed at Outperform. Analysts set price targets to show where they think a stock might trade in the next 12 months. For growth names like INOD, a higher target after this year’s rally gives investors something new to chase. MarketBeat

Innodata’s rally is still running on fundamentals out earlier this quarter. The company reported first-quarter revenue up 54% from a year ago to $90.1 million, with adjusted EBITDA at $25.0 million and gross margin at 47%. Adjusted EBITDA starts with earnings before interest, taxes, depreciation and amortization and includes adjustments Innodata defines. The company raised its 2026 outlook, now seeing revenue growth of about 40% or better. Innodata also said new work with a Big Tech client should add about $51 million to this year’s top line. CEO Jack Abuhoff called it a “record-setting quarter” and said “several potentially large programs” are not yet included in forecasts. Innodata

Bulls point to strong AI demand driving Innodata, with recent results showing profit rising faster than sales. Innodata had $117.4 million in cash and investments and reported no significant debt. Bears see the problem in valuation and customer concentration. INOD traded near 99 times earnings per share. High growth expectations are in the price, so any slip in large AI deals, margins, or customer budgets can hit shares fast. Innodata

Q2 earnings are the next key event for INOD, with management expected to update on the $51 million in Big Tech deals, customer mix, and the 40%+ full-year revenue growth target. At current prices, INOD isn’t obvious value—there’s clear growth and analysts are backing the story, but the stock’s valuation bakes in a lot of execution from a small, high-beta name. Most investors tracking INOD at this point are gauging if AI demand will keep up the pace needed to support the premium.

A technology and finance expert writing for TS2.tech. He analyzes developments in satellites, telecommunications, and artificial intelligence, with a focus on their impact on global markets. Author of industry reports and market commentary, often cited in tech and business media. Passionate about innovation and the digital economy.

Stock Market Today

  • SpaceX IPO's Impact on Rocket Lab Shares and Market Position
    June 16, 2026, 2:30 PM EDT. Space Exploration Technologies (SpaceX) made history with the largest IPO to date, trading at a $2.1 trillion market cap, over 100 times its 2025 revenue forecast of $18 billion. SpaceX's growth hinges on its $11.4 billion Starlink internet service and $26 billion AI contracts from Alphabet and Anthropic, signaling its ambition in AI and space sectors. Conversely, Rocket Lab's shares have dropped 32% since the IPO, reflecting market shift despite its focused business on launching payloads to orbit. Rocket Lab's strategy centers on private rocket launches and satellite technology, offering a differentiated, specialized path in the space economy compared to SpaceX's diversified ambitions. Investors face a choice between SpaceX's expensive, high-growth vision and Rocket Lab's niche operational focus.

Latest articles

Moderna Rises After FDA Review Renews Optimism on mRNA Flu Shot

Moderna Rises After FDA Review Renews Optimism on mRNA Flu Shot

16 June 2026
Moderna shares surged nearly 10% to $57.19 after FDA staff said mFlusiva flu vaccine data may support effectiveness in adults 65+, lowering regulatory risk ahead of a key June 18 advisory panel vote; the next catalyst is the FDA decision by August 5, with the stock’s move standing out as SPY and QQQ fell.
Obai debt swap, city deal push Our Bond stock higher in active trade

Obai debt swap, city deal push Our Bond stock higher in active trade

16 June 2026
Our Bond shares soared 85% to $0.9911 after announcing a $3.3 million debt-for-equity swap priced at $2.0265 per share—over 200% above recent levels—and a citywide AI security platform deployment for 270,000 residents, but ongoing losses, dilution risk, and a stretched balance sheet keep OBAI speculative.
Moderna Rises After FDA Review Renews Optimism on mRNA Flu Shot
Previous Story

Moderna Rises After FDA Review Renews Optimism on mRNA Flu Shot

Go toTop